Jacques Penicaud accompany Dianosic to prepare for launch of its first product (CAVI-T) for the treatment of intranasal bleeding (epistaxis)
As dianosic continues to make headway towards commercialization of its CAVI-T solution in intranasal bleeding, we are excited to inform you that Jacques PENICAUD will support us in preparing the launch of this innovative product.
During his career, Jacques held different positions at Johnson & Johnson ranging from Financial controller to Sales Director and Business Unit Director for the Medical Devices segment (Advanced Wound Care, Ethicon Biosurgery, Mitek and Advanced Sterilization Products). Jacques then pursued an external opportunity as the CEO of STERIENCE (sterilization business) before joining Abbott Vascular as General Manager.
Jacques will leverage his huge experience in the successful launch of disruptive medical technologies to strategize commercialization efforts for our CAVI-T solution.
Jacques, we look forward to disrupting the market together!! ????
#epistaxis #nosebleeds #ENT
